Literature DB >> 30997615

Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain: a randomized double-blind controlled trail-reply.

Fabien Lemoel1, Jacques Levraut2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30997615     DOI： 10.1007/s11739-019-02088-2

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  5 in total

1.  Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain-a randomized double-blind controlled trail: comment.

Authors:  Simon-Pierre Corcostegui; Damien Commeau; Julien Galant; Fabien Ramon; Cédric Boutillier du Retail
Journal:  Intern Emerg Med       Date:  2019-03-12       Impact factor: 3.397

2.  Efficacy and safety of nebulized morphine given at 2 different doses compared to IV titrated morphine in trauma pain.

Authors:  Mohamed Habib Grissa; Hamdi Boubaker; Asma Zorgati; Kaouthar Beltaïef; Wafa Zhani; Mohamed Amine Msolli; Nasri Bzeouich; Wahid Bouida; Riadh Boukef; Semir Nouira
Journal:  Am J Emerg Med       Date:  2015-06-14       Impact factor: 2.469

3.  Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain: a randomized double-blind controlled trial.

Authors:  Fabien Lemoel; Julie Contenti; Charles Cibiera; Jocelyn Rapp; Céline Occelli; Jacques Levraut
Journal:  Intern Emerg Med       Date:  2019-01-01       Impact factor: 3.397

4.  Emergency department crowding is associated with poor care for patients with severe pain.

Authors:  Jesse M Pines; Judd E Hollander
Journal:  Ann Emerg Med       Date:  2007-10-25       Impact factor: 5.721

5.  Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children: The PRIME Randomized Clinical Trial.

Authors:  Theresa M Frey; Todd A Florin; Michelle Caruso; Nanhua Zhang; Yin Zhang; Matthew R Mittiga
Journal:  JAMA Pediatr       Date:  2019-02-01       Impact factor: 16.193
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.